Page last updated: 2024-11-04

rofecoxib and Cancer of Head

rofecoxib has been researched along with Cancer of Head in 2 studies

Research Excerpts

ExcerptRelevanceReference
"Patients with squamous cell carcinoma of the head and neck preoperatively received a specific COX-2 inhibitor (rofecoxib, 25 mg daily) orally for 3 weeks."1.34Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition. ( Andratschke, M; Bergmann, C; Lang, S; Lauffer, L; Lebeau, A; Loehr, I; Mack, B; Moosmann, A; Tiwari, S; Whiteside, TL; Zeidler, R, 2007)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lang, S2
Lauffer, L2
Clausen, C1
Löhr, I1
Schmitt, B1
Hölzel, D1
Wollenberg, B1
Gires, O1
Kastenbauer, E1
Zeidler, R2
Tiwari, S1
Andratschke, M1
Loehr, I1
Bergmann, C1
Mack, B1
Lebeau, A1
Moosmann, A1
Whiteside, TL1

Other Studies

2 other studies available for rofecoxib and Cancer of Head

ArticleYear
Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003, Volume: 17, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Cell Movement; Cyclooxyg

2003
Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.
    Cancer immunology, immunotherapy : CII, 2007, Volume: 56, Issue:10

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Cell Adhesion; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors;

2007